BRAF and melanoma: LGK974 is under clinical investigation in melanoma, pancreatic cancer, triple-negative breast cancer, cervical squamous cell cancer, esophageal squamous cell cancer, lung squamous cell cancer (NCT01351103) and BRAF mutant colorectal cancer (NCT01351103 and NCT02278133).